Correction of Immune Disturbances in Chronic Cerebral Ischemia

Abstract

The aim of the study was to determine efficiency of Glutoxim, aimed for correction of immune disorders. The drug was administered to the patients with chronic cerebral ischemia (CCI, Stage I and II) complicated by arterial hypertension. Increased contents of pro-and anti-inflammatory cytokines, IFNγ, IL-2, G-CSF, and activation of the complement system have been revealed for these conditions, at both functional stages of the disease. The patients with stage II CCI showed elevated markers of oxygen-dependent activity in polymorphonuclear leukocytes (increased levels of spontaneous and stimulated nitroblue tetrazolium (NBT) reduction tests, phagocytic capacity and stimulation index of neutrophils). Stage I of chronic cerebral ischemia was characterized by normal values of NBT reduction tests and functional reserve of neutrophils, along with decreased stimulation index of neutrophils. Among 26 parameters of immune status, 73.1% and 80.8% of indices proved to be changed, respectively, in the patients with stage I and II CCI. 66.7% of immune indices appeared similar in magnitude and direction of changes, whereas the resting 33% are identical in orientation. Usage of Cereton and Actovegin in treatment of the stage I CCI caused normalization of 5.3% immune parameters, with partial normalization of 26.3% tests, and 68.4% of the indexes remaining unchanged or increased posttreatment. Inclusion of Glutoxim into the combined pharmacotherapy proved to be more effective since it totally normalized 52.6% of the indexes, along with partial normalization of 21.1%, while 26.3% of the indicators were not affected by the therapy. Administration of Cereton and Actovegin at the second stage of chronic brain ischemia was followed by partial normalization for 47,6% of the tests, while leaving unchanged or increased 52.4% of the indicators. Glutoxim Use fully normalize 19.0% and partially normalizes 57.1% of immune parameters.

Personalized Pharmacological Correction of Immune Systems, Metabolic and Neuropsychic Parameters in Chronic Brain Ischemia of Stage I and Ii on the Background of Hypertension Disease

“…In order to obtain reliable differences, we combined groups of patients who received Ceretone and Actovegin with patients who received Cerakson and Mexicor, and patients with prescription Cerakson, Mexicor and Glutoxim with patients who received Cerakson, Mexicor and Polyoxidonium [3,4,6,7].…”

“…So, the following fact that the results of the correlation, cluster and factorial analyses are the most informative in the correctional effectiveness of clinical and laboratory parameters in chronic cerebral ischemia stage I has a definition in the plasma concentration of the cytokines TNFα, IL-8, IL-10, stable metabolites of nitric oxide and sorption capacity of the glycocalyx of erythrocytes, and with stage II disease -plasma levels of TNFα, IL-8, IL-17, IL-10, neutrophil phagocytic number and glycocalyx sorption capacity [5,6,7,8], so we selected these parameters for a more detailed analysis.…”

Клініко-Імунологічні Та Адаптаційні Показники При Цереброваскулярних Захворюваннях

“…За даними ВОЗ, вік кожного четвертого інваліда внаслідок судинного ураження мозку не перевищує 45 років (World Health Organization, 2004). Поширеність судинно-мозкових захворювань в нашій країні за 15 років зросла у 4,4 рази 13,14 , а за останні рокив 1,2 рази 15,16 . При цьому підвищилась частота як інсультів та транзиторних порушень мозкового кровообігу (ТПМК) 17 , так і хронічних, повільно прогресуючих форм судинної патології головного мозку, які з часом можуть призвести до розвитку деменції, вплинути на тривалість і якість життя.…”

Effect of vitamin D3 (cholecalciferol) levels on the development of cognitive and psychoemotional disorders in patients with cerebrovascular disease

“…Концентрации hs-CRP 2,1 мг/л [0,2; 7,0], ИЛ-1β 3,3 ± 1,3 пг/мл, ИЛ-6 4,0 ± 2,0 пг/мл у пациентов с ЦВБ была статистически значимо выше, чем у пациентов в группе сравнения: hs-CRP -0,9 мг/л [0,4; 1,9] (p = 0,038), ИЛ-1β -2,1 ± 1,2 пг/мл (p < 0,001), ИЛ-6 -2,5 ± 1,2 пг/мл (p < 0,001), что совпадает с результатами ранее проведенных исследований [13].…”